AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21262858 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 7.5 mg
Number of subjects: 42
Study 21262858 — intervention group
Group type: COMPARATOR
Intervention: glucose (placebo)
Number of subjects: 42
Study 19876544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trials (RCTs)
Number of subjects: 0
Study 19876544 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 16970163 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive behaviour psychotherapy + medicine therapy
Number of subjects: 90
Study 16970163 — intervention group
Group type: COMPARATOR
Intervention: Medicine therapy
Number of subjects: 90
Study 15540688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) in FDB group
Number of subjects: 17
Study 15540688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) in ABF group
Number of subjects: 17
Study 15540688 — intervention group
Group type: COMPARATOR
Intervention: Control group (AAA)
Number of subjects: 17
Study 11583866 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive management strategy
Number of subjects: 1473
Study 11583866 — intervention group
Group type: COMPARATOR
Intervention: Early conservative (medical) management strategy
Number of subjects: 1473
Study 9422950 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (Augmentin)
Number of subjects: 250
Study 9422950 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 250
Study 7839518 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaria oxygen delivery system (75 mg sodium carbonate powder, max flow of 1 l/min for 15 minutes)
Number of subjects: 20
Study 7839518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no oxygen responses)
Number of subjects: 20
Study 3147338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of nitroglycerin to the gum (trinitrolong, TNL)
Number of subjects: 8
Study 3147338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of nitroglycerin to the skin (nitroderm, ND)
Number of subjects: 8
Study 3147338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of nitroglycerin (both TNL and ND)
Number of subjects: 8
Study 29558931 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intervention
Number of subjects: 0
Study 29558931 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium intensity intervention
Number of subjects: 0
Study 29558931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity intervention
Number of subjects: 0
Study 29558931 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation support
Number of subjects: 0
Study 29558931 — intervention group
Group type: COMPARATOR
Intervention: High vs Medium intensity interventions
Number of subjects: 0
Study 27113595 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic Alignment (KA)
Number of subjects: 95
Study 27113595 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Alignment (MA)
Number of subjects: 95
Study 25563522 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment
Number of subjects: 168
Study 25563522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) cultures
Number of subjects: 168
Study 25563522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal cultures
Number of subjects: 168
Study 23110884 — intervention group
Group type: EXPERIMENTAL
Intervention: 15mg of tiagabine
Number of subjects: 15
Study 23110884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21979185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic anorectal endosonography
Number of subjects: 56
Study 21979185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MRI defecography
Number of subjects: 56
Study 21979185 — intervention group
Group type: COMPARATOR
Intervention: Conventional defecography
Number of subjects: 56
Study 18445674 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 at 14,000 IU/wk for 8 weeks (short-term study)
Number of subjects: 365
Study 18445674 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 at 1,400 IU/wk for 1 year (long-term study)
Number of subjects: 365
Study 18445674 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 at 14,000 IU/wk for 1 year (long-term study)
Number of subjects: 365
Study 18445674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (short-term and long-term studies)
Number of subjects: 365
Study 17135177 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Training (WBT) module
Number of subjects: 166
Study 17135177 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face training workshop
Number of subjects: 166
Study 17135177 — intervention group
Group type: COMPARATOR
Intervention: Delayed training control condition
Number of subjects: 166
Study 12880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted retinal vessel measurement for right eye
Number of subjects: 1546
Study 12880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted retinal vessel measurement for left eye
Number of subjects: 1546
Study 12880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriole-to-venule ratio assessment
Number of subjects: 1546
Study 10795116 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg)
Number of subjects: 179
Study 10795116 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75-150 mg)
Number of subjects: 179
Study 8623999 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during induction of anesthesia
Number of subjects: 84
Study 1601756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 2 g intravenously
Number of subjects: 22
Study 1601756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6527751 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of liquid haloperidol daily
Number of subjects: 40
Study 6527751 — intervention group
Group type: COMPARATOR
Intervention: 16 mg of liquid haloperidol daily
Number of subjects: 40
Study 31399794 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-Made Skills Simulator (CMSS)
Number of subjects: 64
Study 31399794 — intervention group
Group type: COMPARATOR
Intervention: da Vinci Skills Simulator (DVSS)
Number of subjects: 64
Study 29293874 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and irinotecan plus bevacizumab (experimental group)
Number of subjects: 487
Study 29293874 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 or CapeOX plus bevacizumab (control group)
Number of subjects: 487
Study 27336840 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty (BK)
Number of subjects: 100
Study 27336840 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Kyphoplasty (RFK)
Number of subjects: 100
Study 24891317 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week
Number of subjects: 215
Study 24891317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 24891317 — intervention group
Group type: COMPARATOR
Intervention: Placebo switched to Etanercept at week 12
Number of subjects: 215
Study 21970137 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg (group M)
Number of subjects: 101
Study 21970137 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg (group P)
Number of subjects: 101
Study 21970137 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 101
Study 19706558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% spinosad creme rinse without nit-combing
Number of subjects: 1038
Study 19706558 — intervention group
Group type: COMPARATOR
Intervention: 1% permethrin with combing
Number of subjects: 1038
Study 19706558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 1038
Study 16916538 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg MPH
Number of subjects: 7
Study 16916538 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg MPH
Number of subjects: 7
Study 16916538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16916538 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 16916538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cocaine
Number of subjects: 7
Study 16916538 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cocaine
Number of subjects: 7
Study 14687240 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year diet intervention (traditional lipid-lowering diet with emphasis on reduction of saturated fat, total caloric intake and body weight)
Number of subjects: 104
Study 14687240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 104
Study 11417034 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepackaged antimalarial drugs
Number of subjects: 0
Study 9286191 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 30
Study 9286191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8103144 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy (LA)
Number of subjects: 140
Study 8103144 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy (OA)
Number of subjects: 140
Study 3526085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg orally bid)
Number of subjects: 10
Study 3526085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3526085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 10
Study 1090132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide, 5 mg
Number of subjects: 18
Study 1090132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide, 5 mg plus Bumetanide, 4 mg
Number of subjects: 18
Study 1090132 — intervention group
Group type: COMPARATOR
Intervention: Bumetanide, 4 mg
Number of subjects: 18
Study 1090132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide, 5 mg plus Spironolactone, 100 mg
Number of subjects: 18
Study 31033612 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercises 3 times per week for 8 weeks
Number of subjects: 40
Study 31033612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 29016995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness instruction (11 minutes)
Number of subjects: 68
Study 29016995 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (active control)
Number of subjects: 68
Study 26083408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensite NavX mapping-guided ablation
Number of subjects: 64
Study 26083408 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic mapping-guided ablation
Number of subjects: 64
Study 26083408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 23816410 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tuberculous therapy for 8 months
Number of subjects: 365
Study 21750555 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine + placebo
Number of subjects: 129
Study 21750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine + 10 mg/kg intetumumab
Number of subjects: 129
Study 21750555 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg intetumumab
Number of subjects: 129
Study 21750555 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg intetumumab
Number of subjects: 129
Study 19434235 — intervention group
Group type: EXPERIMENTAL
Intervention: BmrhGM-CSF (8 microg/kg)
Number of subjects: 19
Study 19434235 — intervention group
Group type: COMPARATOR
Intervention: rhGM-CSF (3.75 microg/kg)
Number of subjects: 19
Study 17255151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group attendance (N = 50)
Number of subjects: 78
Study 17255151 — intervention group
Group type: COMPARATOR
Intervention: No support (Control group, N = 28)
Number of subjects: 78
Study 15023154 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir 900 mg once daily
Number of subjects: 364
Study 15023154 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir 1000 mg three times a day
Number of subjects: 364
Study 11713941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon administered daily
Number of subjects: 77
Study 11713941 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon administered three times weekly
Number of subjects: 77
Study 9236422 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy
Number of subjects: 685
Study 9236422 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer Laser Angioplasty
Number of subjects: 685
Study 9236422 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 685
Study 8213711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 1000 mg/day
Number of subjects: 29
Study 8213711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3305443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX) only
Number of subjects: 504
Study 3305443 — intervention group
Group type: COMPARATOR
Intervention: Cranial radiation and intrathecal methotrexate (IT MTX)
Number of subjects: 504
Study 30016902 — intervention group
Group type: COMPARATOR
Intervention: Standard dose dexamethasone (9.9 mg IV on day 1 and 6.6 mg IV on days 2-4)
Number of subjects: 22
Study 30016902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (3.3 mg IV on days 1-4)
Number of subjects: 22
Study 27353269 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported dosing information (PRDI)
Number of subjects: 404
Study 27353269 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring-based adherence data
Number of subjects: 404
Study 27353269 — intervention group
Group type: EXPERIMENTAL
Intervention: PRDI with a steady-state assumption
Number of subjects: 404
Study 27353269 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring records
Number of subjects: 404
Study 25810849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with epinephrine 1:80,000
Number of subjects: 45
Study 25810849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 3% with Felypressin 0.03 IU/ml
Number of subjects: 45
Study 25810849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 3% plain
Number of subjects: 45
Study 25810849 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study 23631683 — intervention group
Group type: EXPERIMENTAL
Intervention: Jamie Oliver Ministry of Food Program (JMoF) Australia
Number of subjects: 250
Study 23631683 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 250
Study 20941843 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized physiotherapy program (n=150)
Number of subjects: 224
Study 20941843 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy program (n=74)
Number of subjects: 224
Study 17945539 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) monotherapy, 100, 200, 300, and 400mg/day
Number of subjects: 43
Study 16753240 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (Types 6/11/16/18) L1 virus‐like particle (VLP) vaccine
Number of subjects: 1106
Study 16753240 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulations
Number of subjects: 1106
Study 15483207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1079
Study 11454885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (868 women)
Number of subjects: 1716
Study 11454885 — intervention group
Group type: COMPARATOR
Intervention: Observation (848 women)
Number of subjects: 1716
Study 9294907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate dressings
Number of subjects: 51
Study 9294907 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze dressings
Number of subjects: 51
Study 7921311 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite-based nutrition intervention
Number of subjects: 0
Study 7921311 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2870277 — intervention group
Group type: EXPERIMENTAL
Intervention: Different treatments received by the first 130 patients
Number of subjects: 272
Study 2870277 — intervention group
Group type: COMPARATOR
Intervention: Different treatments received by the second group of 142 patients
Number of subjects: 272
Study 2870277 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 272
Study 2870277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved complete remission
Number of subjects: 272
Study 31608934 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1 pmol/kg/min)
Number of subjects: 12
Study 31608934 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (2 pmol/kg/min)
Number of subjects: 12
Study 31608934 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 29064141 — intervention group
Group type: COMPARATOR
Intervention: Dietetic advice and standard diet sheets
Number of subjects: 25
Study 29064141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic advice, diet sheets and use of the smart phone app
Number of subjects: 25
Study 27121277 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping With Strain (CWS) course
Number of subjects: 119
Study 27121277 — intervention group
Group type: COMPARATOR
Intervention: Control group (Intervention Group II - IG2)
Number of subjects: 119
Study 24942170 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week strength training program (TG)
Number of subjects: 12
Study 24942170 — intervention group
Group type: COMPARATOR
Intervention: Standard physical conditioning program (CG)
Number of subjects: 12
Study 22782386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (strength and endurance)
Number of subjects: 204
Study 22782386 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 204
Study 22782386 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 204
Study 22782386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 20083627 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose losartan (150 mg)
Number of subjects: 0
Study 20083627 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation therapy
Number of subjects: 0
Study 20083627 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow left ventricular assist devices
Number of subjects: 0
Study 20083627 — intervention group
Group type: COMPARATOR
Intervention: Atrial synchronized right ventricular pacing
Number of subjects: 0
Study 19260630 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 20 ml R0, 25% preincisional parietal and 20 ml R0, 25% intraperitoneal
Number of subjects: 60
Study 19260630 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 ml normal saline preincisional infiltration and 20 ml R0, 25% intraperitoneal
Number of subjects: 60
Study 19260630 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 20 ml R0, 0.25% preincisional parietal and 20 ml normal saline intraperitoneal
Number of subjects: 60
Study 19260630 — intervention group
Group type: COMPARATOR
Intervention: Group D: 20 ml normal saline preincisional local and 20 ml normal saline intraperitoneal
Number of subjects: 60
Study 16899528 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 152
Study 16899528 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 152
Study 12543742 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% gel
Number of subjects: 57
Study 12543742 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2% injection
Number of subjects: 57
Study 10389775 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg/kg and famotidine 20 mg orally with propofol anesthesia
Number of subjects: 40
Study 10389775 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg/kg and famotidine 20 mg orally with isoflurane anesthesia
Number of subjects: 40
Study 10389775 — intervention group
Group type: COMPARATOR
Intervention: No clonidine premedication with propofol anesthesia
Number of subjects: 40
Study 10389775 — intervention group
Group type: COMPARATOR
Intervention: No clonidine premedication with isoflurane anesthesia
Number of subjects: 40
Study 8537982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose wheat bran fiber (13.5 g/day)
Number of subjects: 95
Study 8537982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcium carbonate (1500 mg/day)
Number of subjects: 95
Study 1795672 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to vanadium pentoxide
Number of subjects: 11
Study 1795672 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to vanadium)
Number of subjects: 11
Study 6337357 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 100
Study 6337357 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 100
Study 31683326 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubators covered for 24 hours (Group 1)
Number of subjects: 32
Study 31683326 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubators open for 24 hours (Group 2)
Number of subjects: 32
Study 31683326 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubators covered for 12 hours and open for 12 hours (Group 3)
Number of subjects: 32
Study 31084966 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan
Number of subjects: 0
Study 31084966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29183873 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51
Study 29183873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27135476 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training Program (PTP), biweekly for 8 weeks, including hurdle and drop jumps
Number of subjects: 28